

Recombinant vaccines for hepatitis E.

<https://www.ncbi.nlm.nih.gov/pubmed/11597521>

Cited in:

Trends Mol Med. 2001 Oct;7(10):462-6.

Recombinant vaccines for hepatitis E.

Emerson SU¹, Purcell RH.

¹ Molecular Hepatitis and Hepatitis Viruses Sections, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. semerson@niaid.nih.gov

Abstract

Hepatitis E virus causes epidemics of acute hepatitis in many developing countries. It infrequently causes disease in developed countries, but avirulent strains might circulate. Some evidence suggests that hepatitis E might be a zoonosis. There is probably only a single serotype. A candidate vaccine consisting of baculovirus-expressed recombinant capsid protein protected macaques from hepatitis E--it passed phase I clinical trials and is currently scheduled for phase II/III clinical trials.

References

Joshi, Y. K., S. Babu, S. Sarin, B. N. Tandon, B. M. Gandhi, and V. C. Chaturvedi. 1985. Immunoprophylaxis of epidemic non-A non-B hepatitis. *Indian J. Med. Res.* 81:18-19.